首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Efficacy of BRL 25000 against Serratia marcescens Enterobacter cloacae and Citrobacter freundii in urinary tract infections.
【2h】

Efficacy of BRL 25000 against Serratia marcescens Enterobacter cloacae and Citrobacter freundii in urinary tract infections.

机译:BRL 25000在尿路感染中对粘质沙雷氏菌阴沟肠杆菌和弗氏柠檬酸杆菌的功效。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Synergism between amoxicillin and clavulanic acid was not expected against cephalosporinase-producing bacterial strains because clavulanic acid has little inhibitory action on cephalosporinases. However, in a clinical trial of BRL 25000 (amoxicillin-clavulanic acid), excellent results were obtained in complicated urinary tract infections caused by Serratia marcescens, Enterobacter cloacae, and Citrobacter freundii strains which produced cephalosporinase and were highly resistant to amoxicillin alone. The good clinical efficacy of BRL 25000 in such urinary tract infections was probably due to the fact that the urinary concentration of clavulanic acid was higher than its minimal inhibitory concentrations for these strains.
机译:预计阿莫西林和克拉维酸之间不会产生头孢菌素酶的细菌协同作用,因为克拉维酸对头孢菌素酶几乎没有抑制作用。然而,在一项BRL 25000(阿莫西林-克拉维酸)的临床试验中,在由粘质沙雷氏菌,阴沟肠杆菌和弗氏柠檬酸杆菌引起的复杂尿路感染中获得了优异的结果,这些菌株产生了头孢菌素酶,并且仅对阿莫西林具有高度耐药性。 BRL 25000在此类尿路感染中具有良好的临床疗效,可能是由于克拉维酸的尿液浓度高于其对这些菌株的最低抑菌浓度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号